<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>) also known as <z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph Disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>), is one of nine polyglutamine (polyQ) diseases caused by a CAG-trinucelotide repeat expansion within the coding sequence of the ATXN3 gene </plain></SENT>
<SENT sid="1" pm="."><plain>There are no disease-modifying treatments for polyQ diseases </plain></SENT>
<SENT sid="2" pm="."><plain>Recent studies suggest that an imbalance in <z:chebi fb="0" ids="15358">histone</z:chebi> acetylation may be a key process leading to transcriptional dysregulation in polyQ diseases </plain></SENT>
<SENT sid="3" pm="."><plain>Because of this possible imbalance, the application of <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase (HDAC) inhibitors may be feasible for the treatment of polyQ diseases </plain></SENT>
<SENT sid="4" pm="."><plain>To further explore the therapeutic potential of HDAC inhibitors, we constructed two independent preclinical trials with <z:chebi fb="0" ids="39867">valproic acid</z:chebi> (VPA), a promising therapeutic HDAC inhibitor, in both Drosophila and cell <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> models </plain></SENT>
<SENT sid="5" pm="."><plain>We demonstrated that prolonged use of VPA at specific dose partly prevented eye <z:e sem="disease" ids="C0162835" disease_type="Disease or Syndrome" abbrv="">depigmentation</z:e>, alleviated climbing disability, and extended the average lifespan of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> transgenic Drosophila </plain></SENT>
<SENT sid="6" pm="."><plain>We found that VPA could both increase the acetylation levels of <z:chebi fb="0" ids="15358">histone</z:chebi> H3 and <z:chebi fb="0" ids="15358">histone</z:chebi> H4 and reduce the early apoptotic rate of cells without inhibiting the aggregation of mutant ataxin-3 proteins in MJDtr-Q68- expressing cells </plain></SENT>
<SENT sid="7" pm="."><plain>These results collectively support the premise that VPA is a promising therapeutic agent for the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> and other polyQ diseases </plain></SENT>
</text></document>